ResMed Inc. vs Snap On Incorporated — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Snap On Incorporated trades at $360.37 (market cap $18.56B). The key difference: ResMed Inc. is the larger of the two by market cap, and Snap On Incorporated pays the higher dividend (2.72%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Snap On Incorporated for 37 Days on average.
| RMD | SNA | |
|---|---|---|
Market Cap | $31.89B | $18.56B |
Volume | 618,314 | 401,326 |
Sector | Health | Industrials |
52-Week High | $277.88 | $419.31 |
52-Week Low | $182.82 | $327.33 |
Typical Hold Time | 51 Days | 37 Days |
Enterprise Value | $31.24B | $18.20B |
Dividend Yield | 1.16% | 2.72% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Snap-On Incorporated (SNA) trades at $360.37, up 0.13% on the day, with a bearish technical outlook but strong fundamentals. The stock shows robust profitability with a 19.6% net income margin and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus is bullish with a $449 price target, though technical indicators signal selling pressure near key resistance at $361.
SNA presents a compelling investment case driven by solid earnings growth and expanding margins, but faces near-term technical headwinds and valuation risks. The stock's premium P/E of 18.31 may limit upside if growth moderates, while institutional activity shows mixed positioning. Investors should weigh strong cash flow against competitive pressures in the tools sector.
Trailing returns across standard periods
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →